A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSIO

Pfizer Limited, Ramsgate Road, Sandwich, Kent UK0 个研究点目标入组 150 人开始时间: 2009年2月20日最近更新: 2017年3月13日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 150

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. One of the following scenarios must be applicable:
•Previously enrolled in B1321001 for at least 4 weeks, was discontinued from the study after the Adjudication Committee granted discontinuation based on early escape or the need to add or increase the dose of a chronic medication for worsening PAH, or
•Previously enrolled in B1321003, discontinued from the study after the Adjudication Committee granted Early Discontinuation due to the need to add or increase the dose of a chronic medication for worsening PAH, or
•Completed the B1321003 study as planned
•2. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
•3. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•4. Has a body weight of =40 kg at the time of the first screening day for B1321001.
•5. If on any medication belonging to the statin drug class (eg, lovastatin, atorvastatin), was receiving a stable dose for at least 3 months prior to the time of the first Screening day for B1321001 and was maintained throughout the study.
•6. Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method), have a negative pregnancy test at Baseline/Day 1 and agree to use reliable methods of contraception for at least 1 month after the final study visit. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Treated with an investigational drug (other than sitaxsentan or sildenafil in either B1321001 or B1321003) or device that has not received regulatory approval within the 30 days prior to Baseline/Day 1 or during the study.
•2. Is taking, or has an anticipated need for systemic administration (oral, intravenous (IV)) of cyclosporine A for the duration of the study.
•3. Is using chronic arginine supplementation including HeartBar®. This must have been stopped for at least 30 days prior to the first Screening day for B1321001.
•4. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Baseline/Day 1.
•5. Has hypotension defined as systolic arterial pressure <90 mm Hg after sitting for 5 minutes at Baseline/Day 1.
•6. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C).
•7. Has hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 times the upper limit of the normal (ULN) range at Baseline/Day 1.
•8. Was discontinued from B1321003 due to AST or ALT >3 times upper limit of normal and a total bilirubin >2 times the upper limit of normal; or AST or ALT >5 times the upper limit of normal.
•9. Experienced a Serious Adverse Event (SAE) categorized as a bleeding event while on B1321003.
•10. Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at first screening day for B1321001 or requires dialytic support.
•11. Has a hemoglobin concentration <10 g/dL at Baseline/Day 1.
•12. History of obstructive sleep apnea (treated or untreated).
•13. History of atrial septostomy.
•14. Has known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischaemic optic neuropathy.
•15. Has untreated proliferative diabetic retinopathy.
•16. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
•17. Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 30 days prior to the time of the first screening day for B1321001 and for the duration of the study.
•18. Is currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
•19. Investigators, study staff or their immediate families.

研究者

发起方

Pfizer Limited, Ramsgate Road, Sandwich, Kent UK

相似试验

进行中（未招募）

不适用

A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSIOMedDRA version: 9.1Level: HLTClassification code 10037401Term: Pulmonary hypertensionsPULMONARY ARTERIAL HYPERTENSION

EUCTR2008-005886-78-BGPfizer Inc., 235 East 42nd Street, New York, NY 10017150

进行中（未招募）

1 期

EUCTR2008-005886-78-CZPfizer Ltd.150

进行中（未招募）

1 期

Phase 3, double-blind randomized, long-term extension safety study designed to obtain additional safety data for 20 mg and 80 mg tafamidis and to continue to provide subjects who have completed 30 months of blinded treatment on Protocol B3461028 with tafamidis for up to 60 additional months, or until subject has access to tafamidis for ATTR-CM via prescription, whichever occurs first.

EUCTR2016-000868-42-ITPFIZER INC1,440

进行中（未招募）

1 期

Phase 3, open label study designed to obtain additional safety data for 20mg and 80mg tafamidis or tafamidis 61mg where available, continue providing to subjects who have completed 30 months of blinded treatment on Protocol B3461028 with tafamidis for up to 60 additional months, or until subject has access to tafamidis for ATTR-CM via prescription. Additional group of patients who have not previously participated in B3461028 included to received tafamidis until local availability by precription.

EUCTR2016-000868-42-GBPfizer Inc.2,000

进行中（未招募）

1 期

EUCTR2016-000868-42-NLPfizer Inc.2,000